Tanaka K, Takechi M, Kamada N
Department of Hematology, Hiroshima University, Japan.
J Radiat Res. 1991 Dec;32(4):378-88. doi: 10.1269/jrr.32.378.
To determine what the role of RAS oncogene is in radiation-induced leukemia, we investigated the frequency of mutations and the sites of the base substitution of activated N- and K-RAS oncogenes in 25 leukemic patients who had been exposed to the atomic bomb and compared the results with those for 47 non-exposed leukemic patients. To detect the presence of mutated RAS oncogene, we used the PCR method to analyze DNAs from leukemic cells and from nude mouse tumors formed by in vivo selection assay. Eight of the 25 exposed leukemic patients (32%) and 13 of the 47 non-exposed leukemic patients (27.6%) had RAS oncogene mutations. No significant differences were found between the exposed and non-exposed groups in frequency of mutation and the sites of base substitution on the RAS oncogene sequence. This study should prove valuable for understanding the role of RAS oncogene mutation in the genesis of radiation-induced leukemias.
为了确定RAS癌基因在辐射诱发白血病中所起的作用，我们调查了25名遭受原子弹辐射的白血病患者中活化的N-RAS和K-RAS癌基因突变频率及碱基替换位点，并将结果与47名未受辐射的白血病患者进行比较。为检测RAS癌基因突变的存在，我们采用聚合酶链反应（PCR）方法分析白血病细胞及通过体内筛选试验在裸鼠体内形成的肿瘤的DNA。25名受辐射的白血病患者中有8名（32%）以及47名未受辐射的白血病患者中有13名（27.6%）存在RAS癌基因突变。在受辐射组和未受辐射组之间，RAS癌基因序列的突变频率和碱基替换位点未发现显著差异。这项研究对于理解RAS癌基因突变在辐射诱发白血病发生过程中的作用应具有重要价值。
